ClinicalTrials.gg
CompletedNCT01197014Updated Apr 27, 2011

A Bioequivalence Study of Amlodipine Plus Losartan Versus Amlodipine and Losartan

A Phase 1 interventional study of Amlodipine plus Losartan and Amlodipine, Losartan in Healthy, sponsored by Hanmi Pharmaceutical Company Limited. Completed at 1 site in Czech Republic. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2011-04-27.

Sponsored by Hanmi Pharmaceutical Company Limited · Phase 1 and Interventional

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
72
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

Study Design :

  • A single center, open, randomized, single dose, two-period, two-treatment, two-sequence, crossover study
Read the detailed description

Primary Objective:

  • To assess the bioequivalence of combination oral formulation of amlodipine/losartan versus two co-administered products containing amlodipine and losartan
02

Conditions studied

  • Healthy

Keywords

  • Amlodipine, Losartan
03

In context

Lead sponsor

Hanmi Pharmaceutical Company Limited is the lead sponsor of 191 studies on the registry; 12 are open to participants now.

Of its 11 completed or terminated interventional studies of FDA-regulated products, 6 (55%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18-55 years
  • Healthy Caucasian volunteers
  • Non smokers or mild smokers

Exclusion criteria

Exclusion criteria:

  • Pregnancy and/or breast-feeding
  • Participation in another clinical trial within 60 days prior to Period 1
05

Study design

Phase
Phase 1
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
72 participants (estimated)

Study arms

  • Experimental
    Amlodipine plus Losartan

    Drug: Amlodipine plus Losartan

  • Active comparator
    Amlodipine, Losartan

    Drug: Amlodipine, Losartan

Interventions

  • DrugAmlodipine plus Losartan

    Drug pages: Amlodipine · Losartan

    Amlodipine/Losartan high dose

  • DrugAmlodipine, Losartan

    Amlodipine, Losartan

06

What researchers measure

Primary outcomes

  1. AUC, Cmax

    Time frame: 0-144hrs

07

Study locations

1 site
  • CEPHA s.r.o.
    Pilsen, Czech Republic
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2010, a primary completion of Nov 2010 and a completion of Dec 2010. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 7, 2010
First posted
Sep 9, 2010
Start
Sep 2010
Primary completionActual
Nov 2010
CompletionActual
Dec 2010
Last update
Apr 27, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 27, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01197014
First posted
Sep 9, 2010
Start date
Sep 2010
Primary completion
Nov 2010
Completion
Dec 2010
Last update
Apr 27, 2011

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Amlodipine · Losartan

Start the discussion